1190393-38-4

Basic information

• Product Name: 2-amino-N-[4-{((2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyroolidin-2-yl)methyl}phenyl]-5,6-dihydro-4H-cyclopenta[α][1,3]thiazole-4-carboxamide
• Synonyms: 2-amino-N-[4-{((2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyroolidin-2-yl)methyl}phenyl]-5,6-dihydro-4H-cyclopenta[α][1,3]thiazole-4-carboxamide
• CAS NO: 1190393-38-4
• Molecular Weight: 448.589
• Mol File: 1190393-38-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-amino-N-[4-{((2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyroolidin-2-yl)methyl}phenyl]-5,6-dihydro-4H-cyclopenta[α][1,3]thiazole-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-N-[4-{((2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyroolidin-2-yl)methyl}phenyl]-5,6-dihydro-4H-cyclopenta[α][1,3]thiazole-4-carboxamide(1190393-38-4)
• EPA Substance Registry System: 2-amino-N-[4-{((2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyroolidin-2-yl)methyl}phenyl]-5,6-dihydro-4H-cyclopenta[α][1,3]thiazole-4-carboxamide(1190393-38-4)

Safety Data

• Hazardous Substances Data: 1190393-38-4(Hazardous Substances Data)

Upstream product

• 2767-70-6 (p-nitrobenzyl)triphenylphosphonium bromide 
• 1190391-89-9 tert-butyl (4R,5R)-2,2-dimethyl-4-[4-(4-nitrophenyl)but-3-en-1-yl]-5-phenyl-1,3-oxazolidine-3-carboxylate 
• 1190391-88-8 (4R,5R)-2,2-dimethyl-4-(3-oxopropyl)-5-phenyl-3-oxazolidinecarboxylic acid 1,1-dimethylethyl ester 
• 1190391-87-7 tert-butyl (4R,5R)-2,2-dimethyl-4-[(1E)-3-oxoprop-1-en-1-yl]-5-phenyl-1,3-oxazolidine-3-carboxylate 
• 1190391-90-2 tert-butyl (2R,5S)-2-[(R)-hydroxy(phenyl)methyl]-5-(4-nitrobenzyl)pyrrolidine-1-carboxylate 
• 1190391-85-5 (2S,5R)-tert-butyl 2-(4-aminobenzyl)-5-((R)-hydroxy(phenyl)methyl)pyrrolidine-1-carboxylate 
• 1190391-81-1 2-((tert-butoxycarbonyl)amino)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxylic acid 
• 1287760-56-8 tert-butyl (2S,5R)-2-(4[({2-[(tert-butoxycarbonyl)amino]-5,6-dihydro-4H-cyclopenta[α][1,3]thiazol-4-yl}carbonyl)amino]benzyl)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidine-1-carboxylate 

Relevant articles and documents

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.